Bio & health

GSK reported updated BEHOLD-1 results for an investigational B7-H4 antibody-drug conjugate in platinum-resistant ovarian cancer.

Randomized Phase 3 results presented at ESMO put sac-TMT’s survival benefit and Merck’s development plans in focus.

Amgen reported Phase 3 results for a maintenance combination in extensive-stage small cell lung cancer.

Bristol Myers Squibb reported a death after an investigational CAR-T treatment in an early multiple-sclerosis study.

The companies presented detailed results for an individualized mRNA vaccine combined with pembrolizumab in high-risk melanoma.

Amgen reported interim Phase 3 results for tarlatamab with durvalumab as first-line maintenance treatment for extensive-stage small-cell lung cancer.

Bristol Myers Squibb disclosed a participant death in an early-stage study of an investigational CAR-T therapy for autoimmune disease.

Moderna and Merck released Phase 3 results early after data from their personalized mRNA melanoma vaccine study leaked ahead of an ESMO presentation.

The proposed Treasury rules would extend outbound-investment controls to biotechnology and other sensitive technology sectors.

The company reported preclinical findings and an update on its Phase 1 peptide-drug conjugate program; efficacy claims remain company-reported and largely preclinical.

Kenya’s health ministry said a 65-year-old woman died after developing symptoms while in quarantine, as authorities reported no evidence of community spread.

Moderna and Merck reported a 42% reduction in melanoma recurrence or death for an investigational vaccine added to Keytruda in a late-stage trial.

AbbVie said lutikizumab met the Phase 3 trial’s primary endpoint, while independent coverage noted the response advantage over placebo was narrower than some expectations.

Detailed Phase 3 results for intismeran autogene plus pembrolizumab showed reductions in recurrence and distant metastasis endpoints versus pembrolizumab alone.

Roivant and Priovant reported positive results from two Phase 3 studies; the indication has not been approved.

A KFF survey found the average worker contribution for family coverage rose to $7,471 in 2026.

The FDA approved bepirovirsen with existing antiviral therapy for a defined group of adults with chronic hepatitis B.

The WHO says a patient in Abuja tested positive after recent travel to Uganda; authorities identified 44 contacts and are tracing exposures.

A first-in-human phase I study tested rapidly manufactured CAR-T cells directed at three B-cell antigens in relapsed or refractory malignancies.

A regulatory filing has reached White House review; the policy text and covered substances are not public.

A proposed interim access policy has reached White House review; its text and scope are not public.

The EMA medicines committee recommended marketing authorization for RASONQUE (daraxonrasib); the European Commission still must decide.

A phase I study reported early clinical outcomes from a locally manufactured CAR T approach for relapsed or treatment-resistant B-cell cancers.

HHS sent an interim compounding policy for certain peptides to the White House for review; no rule or access change has been issued.

HHS sent an interim peptide-compounding policy to White House review; its scope and eventual status remain unsettled.

The second patient was a relative of the first case and had been placed in quarantine, Kenyan authorities said.

The European Commission accepted binding commitments after investigating Sanofi’s communications about a rival influenza vaccine.

Humana says the transaction will fund clinic operations and possible expansion, subject to approvals.

The FTC and state attorneys general allege Shkreli violated a 2022 injunction through pharmaceutical stock trading and public commentary; the court has not ruled.

The proposed reorganization covers research and development, production and global support functions; consultations are beginning.

Reports submitted to regulators have raised concern, but they do not establish that the medicine caused the events.

BMS said the Phase 3 ALOFT-IPF trial met its primary lung-function endpoint at the 60 mg dose; complete results remain pending.

BMS said the interim ACTION-1 analysis met its primary progression-free-survival endpoint in previously treated GEP-NETs.

Caribou said it plans to stop developing vispa-cel and CB-011 while it seeks strategic alternatives amid financing constraints.

The FDA approved pritelivir tablets for specified mucocutaneous HSV lesions in immunocompromised adults whose infections resist standard antivirals.

The FDA cleared a second Phase 2 study of MT027, an investigational allogeneic CAR-T, in brain metastases from lung and breast cancer.

A phase 3 trial reported no clinical benefit from nicotinamide riboside in early Parkinson disease, with the primary outcome favoring placebo.

An independent monitoring committee recommended stopping the study for futility after an interim analysis found it unlikely to meet its primary endpoint.

The company reported early safety observations and visual-field changes in a three-person Phase 1 cohort; the trial is ongoing and the findings are preliminary.

The FDA cleared tucatinib with trastuzumab and pertuzumab for maintenance after induction treatment in adults with unresectable locally advanced or metastatic HER2-positive disease.

The American Hospital Association is challenging a revised drug-discount pilot in court; the legal dispute leaves the program's implementation uncertain.

The company reported interim Phase 1 observations in three participants; the small, early safety study does not establish efficacy.

The FDA approved the hepcidin-mimetic peptide rusfertide for erythrocytosis in adults with polycythemia vera.

A 410-person Phase 3 trial found no clinical benefit from the NAD+ precursor nicotinamide riboside in early Parkinson's disease.

China's drug regulator approved satricabtagene autoleucel for Claudin18.2-positive gastric cancer after at least two prior therapies.

The FDA converted Tecartus from accelerated to traditional approval in relapsed or refractory mantle cell lymphoma, using confirmatory ZUMA-2 data.

Biohub, the U.S. Department of Energy, the NIH and other partners say they will build open data for models that predict how cells respond.

The approval covers adjuvant treatment for adults and children aged 2 years and older.

Two teams used gene-editing-based cellular recorders to reconstruct cell lineages during mouse development.

A mouse study points to a cellular structure that helps sustain pain signaling after nerve injury.

A competition tested AI-designed CD20 binders in CAR-T cells and released its dataset.

A 10-participant study reported gains on some visual tasks, with results varying and normal sight not restored.

Commerce guidance sets out how specialty-product exclusions and urgent-health-need requests fit into the Section 232 pharmaceutical tariff framework.

An Indian multi-site study protocol describes CARE, a multilingual AI conversational interface to be evaluated alongside existing tobacco-cessation services.

A review outlines why promising sensor and machine-learning systems remain difficult to deploy across dairy herds.

The award recognizes discoveries involving light-sensitive ion channels and the development of optogenetics.

The approved plans shift selected medicines from upfront 340B discounts to claims-based rebates beginning January 1, 2027.

Novo Nordisk says the FDA extended its review while manufacturing-site remediation continues; the company reports no new action date.

A targeted niclosamide formulation reduced lesion burden and pain-associated behavior in a mouse model; human efficacy remains untested.

CAR-T resets, antigen-specific tolerance, engineered regulatory T cells and AI-assisted tools share one aim: retrain the immune system rather than only silence it. Most of the evidence is still early.

The companies are expanding their immunology collaboration with a new group of antibody medicines.

Nature examines coral heat stress alongside experimental work on microbial probiotics and sound-based interventions.

ARPA-H says the program will combine adaptive trial design, computational models and real-time analysis; STAT reports that funding details were not included in the initial announcement.

A clinical study describes a tick-associated virus identified among patients with febrile illness in China.

A 15-participant phase 1a study reported sustained lipid reductions one year after a single infusion.

A newly described tick-borne virus was identified in a study of febrile patients in China.

The reported viral sequences have not yet been shown to perform a CRISPR-like function.

A small first-in-human study reported sustained lipid reductions at one-year follow-up.

A preprint describes Minerva, a genome-language-model framework for mapping sequence interactions; the reported viral repeat patterns still lack confirmed function.

A mouse study found that tirzepatide activated brown fat through effects not explained by reduced food intake alone.

The reported sequence pattern is a research lead; its biological function has not been established.

The approval adds a weekly basal insulin option for adults with type 2 diabetes; Lilly says its Phase 3 program included more than 3,400 participants.

A Rutgers analysis of FDA dockets found that most comments were form letters, with many traceable to tobacco-industry campaigns.

Biomedical coverage describes AI in lab workflows, clinical trials and radiology.

Two reports raise different questions about GLP-1 medicines and weight-related outcomes.

Public-health reporting on a U.S. outbreak sits alongside research coverage on emerging infectious diseases.

The FDA approved Onswik, Lilly’s once-weekly basal insulin for adults with type 2 diabetes.

An FDA advisory panel backed Grail’s multi-cancer blood test on benefit-risk questions; the agency has not made its approval decision.

A claims-based study reported nutritional deficiency diagnoses among pediatric GLP-1 receptor agonist users.

A UK Biobank analysis linked measured sleep stages with later disease incidence across a broad set of outcomes.

Deployment research focused on how AI changes clinical roles and how its outcomes should be measured.

The panel vote moves multi-cancer early detection toward an FDA decision that also gates insurance coverage.

New papers tested clinical LLMs on stability, bias and reproducibility rather than headline accuracy.

Registry updates showed new and established sponsors across RAS inhibition, prostate, uterine and brain cancers.

Investors are returning to bone-loss therapies as evidence for common supplements looks thin.

A preprint used genomic language modelling to design biosynthetic pathways while clinical work pushed new biomarkers.

New work argues the human and workflow context around a clinical AI matters more than how it explains itself.

Machine-learning prediction and monitoring studies clustered around acute and critical care.

Cancer news spanned an FDA advisory vote, a new approval and registered combination trials.

Novo's Medicare pricing terms and fresh evidence on stopping GLP-1 drugs both landed the same day.

AI-assisted modelling and triage tools met a resurgent filovirus and a deep-time lesson on plague.

Brain science ranged from a two-organ hypothesis to implants, long-COVID imaging and dementia prediction.

Resilience, not only pathology, is emerging as the predictive variable in dementia research.

A Galleri advisory-committee vote, a Lilly approval and a radiopharma merger set the day's regulatory tone.

Clinical AI moved from benchmarks toward deployment — and one paper flagged a gap between algorithmic scores and decisions.

Editing and RNA therapies advanced, and researchers solved a 50-year mystery by finding a new human blood group.

A capital-markets-day reset for Novo landed alongside a meta-regression on GLP-1 stroke and cognitive outcomes.

Flu antigenic drift, repeated SARS-CoV-2 introductions and a surging Ebola relative point to the value of early warning.

An effectiveness study and a trust-and-information story show the two halves of the vaccination problem.

New disease models, an Amish cohort study and an analysis of repurposing candidates all point at the same target from different directions.

A first-in-human neuromodulation trial overlaps with basic work on how amygdala neurons join valence-related ensembles and with a developmental study of anxiety.

Papers on AI in trials, patient-facing generative AI and a geriatrician's commentary converge on evaluation as the binding constraint.

Observational diet research and two cardiovascular studies on gut microbiota and on religiosity add to the evidence base without settling causation.

An approval for an ultra-rare disease arrived alongside preclinical gene-therapy work and a review of CRISPR-based biosensors.

New and updated registry entries spanned AI cardiac imaging, a supplement trial, metabolic and oncology studies, and an AI review of diabetes self-management.